AstraZeneca gains 5% on marketing nod to launch cancer drug in India

The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.

AstraZeneca Pharma India was up 5% to Rs 1,416 on the BSE in early morning trade after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.

“The company has received import & market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses,” AstraZeneca Pharma India said in a press release.

Durvalumab provides a